These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 22941289)

  • 1. The important roles of RET, VEGFR2 and the RAF/MEK/ERK pathway in cancer treatment with sorafenib.
    Mao WF; Shao MH; Gao PT; Ma J; Li HJ; Li GL; Han BH; Yuan CG
    Acta Pharmacol Sin; 2012 Oct; 33(10):1311-8. PubMed ID: 22941289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VEGFR, RET, and RAF/MEK/ERK pathway take part in the inhibition of osteosarcoma MG63 cells with sorafenib treatment.
    Mei J; Zhu X; Wang Z; Wang Z
    Cell Biochem Biophys; 2014 May; 69(1):151-6. PubMed ID: 24375110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iodide- and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancer.
    Ruan M; Liu M; Dong Q; Chen L
    J Clin Endocrinol Metab; 2015 May; 100(5):1771-9. PubMed ID: 25768669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib.
    Yokoi K; Kobayashi A; Motoyama H; Kitazawa M; Shimizu A; Notake T; Yokoyama T; Matsumura T; Takeoka M; Miyagawa SI
    Oncol Rep; 2018 Feb; 39(2):843-850. PubMed ID: 29251327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro.
    Koh YW; Shah MH; Agarwal K; McCarty SK; Koo BS; Brendel VJ; Wang C; Porter K; Jarjoura D; Saji M; Ringel MD
    Endocr Relat Cancer; 2012 Feb; 19(1):29-38. PubMed ID: 22109971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
    Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
    Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Capsaicin enhances the antitumor activity of sorafenib in hepatocellular carcinoma cells and mouse xenograft tumors through increased ERK signaling.
    Zhang SS; Ni YH; Zhao CR; Qiao Z; Yu HX; Wang LY; Sun JY; Du C; Zhang JH; Dong LY; Wang K; Gao JJ
    Acta Pharmacol Sin; 2018 Mar; 39(3):438-448. PubMed ID: 29188798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitamin K1 enhances sorafenib-induced growth inhibition and apoptosis of human malignant glioma cells by blocking the Raf/MEK/ERK pathway.
    Du W; Zhou JR; Wang DL; Gong K; Zhang QJ
    World J Surg Oncol; 2012 Apr; 10():60. PubMed ID: 22520038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apatinib affect VEGF-mediated cell proliferation, migration, invasion via blocking VEGFR2/RAF/MEK/ERK and PI3K/AKT pathways in cholangiocarcinoma cell.
    Huang M; Huang B; Li G; Zeng S
    BMC Gastroenterol; 2018 Nov; 18(1):169. PubMed ID: 30400838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement.
    Henderson YC; Ahn SH; Kang Y; Clayman GL
    Clin Cancer Res; 2008 Aug; 14(15):4908-4914. PubMed ID: 18676765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mathematical modelling unveils the essential role of cellular phosphatases in the inhibition of RAF-MEK-ERK signalling by sorafenib in hepatocellular carcinoma cells.
    Saidak Z; Giacobbi AS; Louandre C; Sauzay C; Mammeri Y; Galmiche A
    Cancer Lett; 2017 Apr; 392():1-8. PubMed ID: 28161506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
    Ou DL; Shen YC; Liang JD; Liou JY; Yu SL; Fan HH; Wang DS; Lu YS; Hsu C; Cheng AL
    Clin Cancer Res; 2009 Sep; 15(18):5820-8. PubMed ID: 19737956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential inhibitory effects of two Raf-targeting drugs, sorafenib and PLX4720, on the growth of multidrug-resistant cells.
    Eum KH; Ahn SK; Kang H; Lee M
    Mol Cell Biochem; 2013 Jan; 372(1-2):65-74. PubMed ID: 22941213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib regulating ERK signals pathway in gastric cancer cell.
    Juan LW; En LM; Hao L; Kai HY; Ju H
    Environ Toxicol Pharmacol; 2014 Sep; 38(2):438-43. PubMed ID: 25136776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines.
    Kim JS; Choi GH; Jung Y; Kim KM; Jang SJ; Yu ES; Lee HC
    J Cancer Res Clin Oncol; 2018 Aug; 144(8):1487-1501. PubMed ID: 29858683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-proliferative actions of N'-desmethylsorafenib in human breast cancer cells.
    Cui PH; Rawling T; Gillani TB; Bourget K; Wang XS; Zhou F; Murray M
    Biochem Pharmacol; 2013 Aug; 86(3):419-27. PubMed ID: 23732299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
    Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
    J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway.
    Peng CL; Guo W; Ji T; Ren T; Yang Y; Li DS; Qu HY; Li X; Tang S; Yan TQ; Tang XD
    Cancer Biol Ther; 2009 Sep; 8(18):1729-36. PubMed ID: 19633425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The regulation of ERK and p-ERK expression by cisplatin and sorafenib in gastric cancer cells.
    Tao C; Lin H; Chen S
    Gene; 2014 Nov; 552(1):106-15. PubMed ID: 25219752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
    Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
    Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.